Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

Contact Us

Search

Paroxysmal Nocturnal Hemoglobinuria

Rare Disease news

Rare Disease Today—January 8, 2026

This rare disease update covers major regulatory approvals, strategic…

Artificial_Intelligence

AI in Healthcare and Digital Health Today—December 15, 2025

This AI in Healthcare and Digital Health update highlights the biggest…

Hematology

Latest Hematology News - Sept 22nd to Oct 6th 2025

Watch Our Video Summary Capturing Top Hematology News from the Last Two Weeks…

EHA 2025_Preview_by_LucidQuest

EHA 2025 Preview: Key Hematology Highlights to Watch

EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Vaccines Video Recap—February 6, 2026
Respiratory Video Recap—February 6, 2026
Public Health Today—February 6, 2026
Vaccines Today—February 6, 2026

Tags

advanced therapies AI for Science AIM Vaccine allogeneic CAR-T AN2 Therapeutics bioinformatics Biologic therapies Bispecific antibody therapy cancer ckd corporate venture capital Digital Medicine Society drug pricing drug supply chain Elranatamab ESMO 2021 FDA fast track FDA oncology approvals FDA Priority Review gene editing gene therapy approval Gene therapy innovation Global neuroscience market hematology investment In vivo CRISPR editing Knowledge graphs Merck Healthcare Korea nanotechnology NFTs in healthcare non viral vectors Obesity strategy oncology trials pharma Public health market trends Recessive dystrophic epidermolysis bullosa remote patient monitoring Reproductive health therapies Respiratory drug pipeline Sema4 T-cell engagers testicular germ cell tumor tissue engineering TNFα unconventional trial designs

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Vaccines Video Recap—February 6, 2026
Respiratory Video Recap—February 6, 2026
Public Health Today—February 6, 2026
Vaccines Today—February 6, 2026

TAGS

advanced therapies AI for Science AIM Vaccine allogeneic CAR-T AN2 Therapeutics bioinformatics Biologic therapies Bispecific antibody therapy cancer ckd corporate venture capital Digital Medicine Society drug pricing drug supply chain Elranatamab ESMO 2021 FDA fast track FDA oncology approvals FDA Priority Review gene editing gene therapy approval Gene therapy innovation Global neuroscience market hematology investment In vivo CRISPR editing Knowledge graphs Merck Healthcare Korea nanotechnology NFTs in healthcare non viral vectors Obesity strategy oncology trials pharma Public health market trends Recessive dystrophic epidermolysis bullosa remote patient monitoring Reproductive health therapies Respiratory drug pipeline Sema4 T-cell engagers testicular germ cell tumor tissue engineering TNFα unconventional trial designs

Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy